---

Business of the House

I wish to raise with the Leader of the House the tragic case of my constituent, Mr. Roy Harward, who is suffering from mesothelioma and ask whether we may have a debate on the treatment of—not compensation for—that disease. One drug, Alimta, is licensed in this country to treat the symptoms and pain caused by mesothelioma. It can prolong life by two to three months, possibly more, but it is prescribed under a postcode lottery. If my constituent lived in Scotland, or the north-east or north-west of England, he could be prescribed that drug, but he has just had funding for treatment with Alimta refused by the local primary care trust. May we debate this issue in the House or have an urgent statement by the Secretary of State for Health, because it is unthinkable and unethical that my constituent is dying but cannot get the treatment he needs to alleviate his pain and prolong his life. There is no point—